These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 32460142)

  • 21. Association Between Sublingual Buprenorphine-Naloxone Exposure and Dental Disease.
    Etminan M; Rezaeianzadeh R; Kezouh A; Aminzadeh K
    JAMA; 2022 Dec; 328(22):2269-2271. PubMed ID: 36511932
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Buprenorphine/naloxone: a review of its use in the treatment of opioid dependence.
    Orman JS; Keating GM
    Drugs; 2009; 69(5):577-607. PubMed ID: 19368419
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High-dose buprenorphine for treatment of high potency opioid use disorder.
    Danilewitz M; McLean M
    Drug Alcohol Rev; 2020 Feb; 39(2):135-137. PubMed ID: 31769109
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Is there enough naloxone to deter the diversion? Effect of concurrent administration of intravenous naloxone on opioid agonist effects of intravenous buprenorphine: A randomised, double-blind, within-subject, crossover study among opioid-dependent subjects.
    Dhagudu NK; Ambekar A; Agrawal A; Rao R; Mishra AK; Jain R; Singh S
    Drug Alcohol Rev; 2020 Jul; 39(5):595-603. PubMed ID: 32162420
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Successful rotation from long-acting full agonist opioids to sublingual buprenorphine/naloxone using a microdosing approach.
    Vytialingam RC; Schug SA; O'Regan R
    J Opioid Manag; 2021; 17(7):159-166. PubMed ID: 34520037
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Buprenorphine-naloxone buccal soluble film for the treatment of opioid dependence: current update.
    Soyka M
    Expert Opin Drug Deliv; 2015 Feb; 12(2):339-47. PubMed ID: 25156759
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Successful Buprenorphine/Naloxone Low-dose Induction in Pregnancy: A Case Report.
    Coish R; Hardial J
    J Addict Med; 2023 Jan-Feb 01; 17(1):114-116. PubMed ID: 35916416
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of a sublingual buprenorphine/naloxone rapidly dissolving tablet for the treatment of adults with opioid dependence: A randomized trial.
    Webster L; Hjelmström P; Sumner M; Gunderson EW
    J Addict Dis; 2016; 35(4):325-338. PubMed ID: 27267785
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety of a Rapidly Dissolving Buprenorphine/Naloxone Sublingual Tablet (BNX-RDT) for Treatment of Opioid Dependence: A Multicenter, Open-label Extension Study.
    Hoffman K; Peyton ML; Sumner M
    J Addict Med; 2017; 11(3):217-223. PubMed ID: 28353467
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Does the Addition of Naloxone in Buprenorphine/Naloxone Affect Retention in Treatment in Opioid Replacement Therapy?: A Systematic Review and Meta-Analysis.
    Dalton K; Butt N
    J Addict Nurs; 2019; 30(4):254-260. PubMed ID: 31800516
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Buprenorphine/Naloxone (Zubsolv
    Heo YA; Scott LJ
    CNS Drugs; 2018 Sep; 32(9):875-882. PubMed ID: 30117074
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    Haight BR; Learned SM; Laffont CM; Fudala PJ; Zhao Y; Garofalo AS; Greenwald MK; Nadipelli VR; Ling W; Heidbreder C;
    Lancet; 2019 Feb; 393(10173):778-790. PubMed ID: 30792007
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of buprenorphine versus buprenorphine/naloxone tablets in non-dependent opioid abusers.
    Strain EC; Stoller K; Walsh SL; Bigelow GE
    Psychopharmacology (Berl); 2000 Mar; 148(4):374-83. PubMed ID: 10928310
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Transition from Oxycodone to Buprenorphine/Naloxone in a Hospitalized Patient with Sickle Cell Disease: A Case Report.
    Leyde S; Suen L; Pratt L; DeFries T
    J Gen Intern Med; 2022 Apr; 37(5):1281-1285. PubMed ID: 34993878
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical experience with fortnightly buprenorphine/naloxone versus buprenorphine in Italy: preliminary observational data in an office-based setting.
    Amato P
    Clin Drug Investig; 2010; 30 Suppl 1():33-9. PubMed ID: 20450244
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Primary care management of opioid use disorders: Abstinence, methadone, or buprenorphine-naloxone?
    Srivastava A; Kahan M; Nader M
    Can Fam Physician; 2017 Mar; 63(3):200-205. PubMed ID: 28292795
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Medication-Assisted Treatment of Opioid Use Disorder in Adolescents and Young Adults.
    Cottrill CB; Matson SC
    Adolesc Med State Art Rev; 2014 Aug; 25(2):251-65. PubMed ID: 27132312
    [No Abstract]   [Full Text] [Related]  

  • 38. Treating opioid use disorder with rapid micro induction technique of sublingual buprenorphine/naloxone in an outpatient setting-a case report.
    Martell JP; Konakanchi JS; Sethi R
    J Addict Dis; 2022; 40(3):439-443. PubMed ID: 35072589
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapeutic switch to buprenorphine/naloxone from buprenorphine alone: clinical experience in an Italian addiction centre.
    Montesano F; Zaccone D; Battaglia E; Genco F; Mellace V
    Clin Drug Investig; 2010; 30 Suppl 1():13-9. PubMed ID: 20450241
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety of the newer class of opioid antagonists in pregnancy.
    Poon S; Pupco A; Koren G; Bozzo P
    Can Fam Physician; 2014 Jul; 60(7):631-2, e348-9. PubMed ID: 25022635
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.